Invested in Indee Labs from the BroadOak BioTools Venture Fund.
APR 12, 2023
Develops and sells Hydropore, a scalable non-viral microfluidic vortex-shedding platform and instruments for delivering nucleic acids, proteins, small molecules, and gene-editing complexes into immune cells
Develops and sells Hydropore, a scalable non-viral microfluidic vortex-shedding platform and instruments for delivering nucleic acids, proteins, small molecules, and gene-editing complexes into immune cells. The technology supports engineered cell therapy research and manufacturing, including T-cell immunotherapies, while preserving cell viability and function.